PWR
60
2
SE
77
5
O
30
-3
URBN
55
3
AVGO
42
2
FTI
56
-5
TROW
58
4
CTAS
53
8
PNC
59
2
HAL
50
4
PCAR
30
-4
A
53
5
ADSK
53
-4
AXP
66
2
NFLX
57
4
SWK
39
2
XOM
54
-2
ITW
50
10
ORCL
63
4
EQIX
50
2
PWR
60
2
SE
77
5
O
30
-3
URBN
55
3
AVGO
42
2
FTI
56
-5
TROW
58
4
CTAS
53
8
PNC
59
2
HAL
50
4
PCAR
30
-4
A
53
5
ADSK
53
-4
AXP
66
2
NFLX
57
4
SWK
39
2
XOM
54
-2
ITW
50
10
ORCL
63
4
EQIX
50
2
Financhill
Back

ImmunoPrecise Antibodies 10K Form

Sell
49

IPA
ImmunoPrecise Antibodies

Last Price:
$1.8000
Seasonality Move:
419.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IPA News And Ratings

See the #1 stock for the next 7 days that we like better than IPA

IPA Financial Statistics

Sales & Book Value

Annual Sales: $18.2M
Cash Flow: $-783.8K
Price / Cash Flow: 0
Annual Sales: $0.56
Price / Book: 4.59

Profitability

EPS (TTM): -1.16850
Net Income (TTM): $-33.6M
Gross Margin: $8.9M
Return on Equity: -132.89%
Return on Assets: -76.46%

ImmunoPrecise Antibodies Earnings Forecast

Key ImmunoPrecise Antibodies Financial Ratios

  • The Gross Profit Margin over the past 17 years for IPA is 49.16%.
  • The Selling, General & Administrative Expenses for IPA have been equal to 78.04% of Gross Profit Margin.
  • The Research & Development expenses have been 16.49% of Revenue.
  • The Net Earning history of IPA is -110.85% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 16 years.

ImmunoPrecise Antibodies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: IPA
Website: ipatherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.32
Quick Ratio: 1.99

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IPA Technical Analysis vs Fundamental Analysis

Sell
49
ImmunoPrecise Antibodies (IPA) is a Sell

Is ImmunoPrecise Antibodies a Buy or a Sell?